|
Private Sector | Telangana - India | PID: 193869
|
Indian Immunologicals (IIL) has commenced work on Rs 75 crore viral antigen manufacturing facility in Genome Valley, Telangana, that will enhance its viral vaccine making capacity by 35 percent by October 2021
The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential COVID-19 inoculation. The new viral antigen facility will be specially designed as a multi-product facility
IIL also inaugurated a sterile filling facility that has come up with an investment of Rs 75 crore. The new facility will boost IIL’s manufacturing capacity 35 percent and the new plant is expected to be completed by October 2021
It will be a Biosafety level-2 and -3-compliant plant. Biosafety level-3 plants are appropriate for work involving microbes, which could cause serious and potentially lethal diseases, through the inhalation route
The company also plans to utilise the cutting-edge facility to manufacture COVID-19 vaccines post completion of its R&D with Griffith University, Australia
As for the sterile filling facility, it will increase IIL’s capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) Abhayrab
As part of the expansion plan, IIL will add over 150 new positions, bringing its total staff strength close to 1,500
IIL has four manufacturing facilities at various locations: Karkapatla, Telangana, for human vaccines & animal health formulations; Ooty, Tamil Nadu, for anti-rabies; Hyderabad, Telangana, for human biologicals (Gachibowli) and animal vaccines; and Dargaville, New Zealand
| Updated on: 27 - Nov - 2020
|
|
|
|